 Livemint | Cancer drugs to help Cipla sales hit $7 billion Livemint India's third-largest drug maker by market value predicts revenue may rise to as much as $7 billion (around Rs.38,122 crore) selling medicines in the continent that's home to about 800 million people, said Chandru Chawla, head of international business ... |
